[go: up one dir, main page]

MXPA03005960A - Nuevas mezclas de enzimas microbianas. - Google Patents

Nuevas mezclas de enzimas microbianas.

Info

Publication number
MXPA03005960A
MXPA03005960A MXPA03005960A MXPA03005960A MXPA03005960A MX PA03005960 A MXPA03005960 A MX PA03005960A MX PA03005960 A MXPA03005960 A MX PA03005960A MX PA03005960 A MXPA03005960 A MX PA03005960A MX PA03005960 A MXPA03005960 A MX PA03005960A
Authority
MX
Mexico
Prior art keywords
microbial enzymes
novel mixtures
mixtures
novel
microbial
Prior art date
Application number
MXPA03005960A
Other languages
English (en)
Inventor
Galle Manfred
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144711A external-priority patent/DE10144711A1/de
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of MXPA03005960A publication Critical patent/MXPA03005960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA03005960A 2001-01-19 2002-01-16 Nuevas mezclas de enzimas microbianas. MXPA03005960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10102495 2001-01-19
DE10144711A DE10144711A1 (de) 2001-01-19 2001-09-11 Neue Gemische mikrobieller Enzyme
PCT/EP2002/000374 WO2002060474A2 (de) 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion

Publications (1)

Publication Number Publication Date
MXPA03005960A true MXPA03005960A (es) 2003-09-05

Family

ID=26008287

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005960A MXPA03005960A (es) 2001-01-19 2002-01-16 Nuevas mezclas de enzimas microbianas.

Country Status (17)

Country Link
US (1) US20040057944A1 (es)
EP (1) EP1381386A2 (es)
JP (1) JP2004524838A (es)
CN (1) CN1236817C (es)
AR (1) AR032392A1 (es)
BR (1) BR0206521A (es)
CA (1) CA2434808A1 (es)
CZ (1) CZ20031900A3 (es)
HU (1) HUP0500560A3 (es)
IL (1) IL157004A0 (es)
MX (1) MXPA03005960A (es)
NO (1) NO20033261D0 (es)
NZ (1) NZ527148A (es)
PL (1) PL362646A1 (es)
RU (1) RU2003124078A (es)
SK (1) SK9292003A3 (es)
WO (1) WO2002060474A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) * 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US7459155B2 (en) * 2003-10-29 2008-12-02 Altus Pharmaceuticals Inc. Treating abdominal pain due to pancreatitis with seaprose
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
DK1755656T3 (da) * 2004-05-24 2010-10-04 Novozymes As Enzymer til farmaceutisk anvendelse
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006044529A1 (en) * 2004-10-14 2006-04-27 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
NZ563693A (en) * 2005-06-24 2010-08-27 Novozymes As Lipases derived from Thermocyces lanuginosus optionally in combination with a protease and/or amylase for pharmaceutical use
JP2008546395A (ja) * 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 医薬使用のためのプロテアーゼ
NZ563737A (en) * 2005-06-24 2010-08-27 Novozymes As Amylases derived from Bacillus stearothermophilus optionally in combination with proteases and/or lipases for pharmaceutical use
EP2278002B1 (en) * 2005-07-29 2017-07-12 Abbott Laboratories GmbH Pancreatin with reduced viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DE602006004471D1 (de) * 2005-08-15 2009-02-05 Solvay Pharm Gmbh Pankreatin-mikropellets geeignet für magensaftresistente überzüge
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20100196344A1 (en) * 2005-10-14 2010-08-05 Cystic Fibrosis Foundation Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP2010510310A (ja) 2006-11-22 2010-04-02 スタンダード バイオロジックス インコーポレイテッド コウジカビプロテアーゼを使用する処置の方法
BRPI0721103A2 (pt) 2006-12-21 2014-03-04 Novozymes As Lipase, método de determinação do desempenho da digestão in vitro de uma lipase em comparação com uma lipase de referência, uso de uma lipase ou de uma mistura de lipases, composição farmacêutica, e, método para o tratamento de doença
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US8246950B2 (en) 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
US20090068174A1 (en) * 2007-09-12 2009-03-12 Kansas University Medical Center Research Institute, Inc. Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
KR20100092450A (ko) 2007-12-04 2010-08-20 노보자임스 에이/에스 약학적 사용을 위한 프로테아제 변이체
CA2711187A1 (en) * 2008-01-03 2009-07-09 George Shlieout Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) * 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328566A1 (en) * 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
WO2010080830A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
BRPI1007379B8 (pt) 2009-01-06 2022-07-19 Curemark Llc composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
WO2011114224A1 (en) * 2010-03-19 2011-09-22 Axcan Pharma Inc. Gastro-resistant enzyme pharmaceutical compositions
CN108187033A (zh) 2010-10-01 2018-06-22 阿普塔利斯制药有限公司 肠溶包衣的低强度胰脂肪酶制剂
CA2822637C (en) 2010-12-22 2020-06-30 Novozymes North America, Inc. Processes for producing fermentation products
BR112013027034A8 (pt) 2011-04-21 2018-01-02 Curemark Llc "compostos para o tratamento de transtornos neuropsiquiátricos."
ES2558756T3 (es) 2011-08-08 2016-02-08 Aptalis Pharma Limited Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
EA201491087A1 (ru) * 2011-12-02 2014-09-30 Новозимс А/С Способы получения продуктов ферментации
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
KR102198633B1 (ko) 2012-09-19 2021-01-05 그레스포 에이비 뇌기능 향상용 조성물
MX2015012078A (es) 2013-03-15 2016-04-15 Allergan Pharmaceuticals Internat Ltd Composicion que contiene enzimas digestivas y nutrientes adecuados para la administracion enteral.
WO2014209789A1 (en) 2013-06-24 2014-12-31 Novozymes A/S Process of extracting oil from thin stillage
US11939552B2 (en) 2013-06-24 2024-03-26 Novozymes A/S Process of recovering oil
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
WO2015069677A1 (en) * 2013-11-05 2015-05-14 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
JP2016527247A (ja) * 2013-07-22 2016-09-08 アラガン ファーマシューティカルズ インターナショナル リミテッド 高力価パンクレアチン医薬組成物
EP3030257B1 (en) 2013-08-09 2020-02-19 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US20180028454A1 (en) * 2015-02-04 2018-02-01 Abbvie Inc. Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US20200291375A1 (en) * 2017-09-24 2020-09-17 Bio-Cat, Inc. Fungal protease mixtures and uses thereof
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
FR3111559A1 (fr) * 2020-06-18 2021-12-24 Azurrx Biopharma, Inc. Formulations non porcines et leurs procédés
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084431A (en) * 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE2638088C3 (de) * 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
JP3152958B2 (ja) * 1991-06-14 2001-04-03 天野エンザイム株式会社 微生物起源リパーゼの安定化組成物及び安定化法
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament

Also Published As

Publication number Publication date
AR032392A1 (es) 2003-11-05
RU2003124078A (ru) 2005-01-27
CN1236817C (zh) 2006-01-18
NO20033261L (no) 2003-07-18
EP1381386A2 (de) 2004-01-21
WO2002060474A2 (de) 2002-08-08
HUP0500560A3 (en) 2006-06-28
PL362646A1 (en) 2004-11-02
NZ527148A (en) 2005-01-28
WO2002060474A3 (de) 2003-10-30
CA2434808A1 (en) 2002-08-08
CN1487837A (zh) 2004-04-07
IL157004A0 (en) 2004-02-08
US20040057944A1 (en) 2004-03-25
HUP0500560A2 (hu) 2005-09-28
BR0206521A (pt) 2004-02-17
CZ20031900A3 (cs) 2003-10-15
SK9292003A3 (en) 2003-12-02
JP2004524838A (ja) 2004-08-19
NO20033261D0 (no) 2003-07-18

Similar Documents

Publication Publication Date Title
MXPA03005960A (es) Nuevas mezclas de enzimas microbianas.
AU2002357860A8 (en) Enzymes
AU2001271427A1 (en) Novel proteases
AU7961401A (en) Subtilase enzymes
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
GB0017387D0 (en) Novel enzyme
MXPA03007043A (es) Nueva sal de succinato de o-desmetil-venlafaxina.
AU2003238930A1 (en) Enzymes
MXPA03007130A (es) Conjugados de peg de hgf-nk4.
AU2002347778A1 (en) Enzymes
AU2002358179A1 (en) New rennets
EP1572877A3 (en) Drug metabolizing enzymes
AU2001285693A1 (en) Bio-reactor
AU2002243922A1 (en) Ap1 amine oxidase variants
ZA200304986B (en) Novel mixtures of microbial enzymes.
AU2003216376A1 (en) Enzymes
AU2002257273A1 (en) Enzymes
AU2003220607A1 (en) Enzymes
AU2003225282A1 (en) Enzymes
AU2002236595A1 (en) Enzymes
AUPR482001A0 (en) Metal-handling enzymes
AUPS282802A0 (en) Novel enzymes
AU2003287338A8 (en) Microbial enzymes having multiple improved characteristics
GB0102946D0 (en) Enzyme
GB0121840D0 (en) Modified enzyme